Pfizer has so far delivered close to 1.5 million doses of its Covid-19 vaccine to Hungary in regular weekly shipments, Pfizer Gyógyszerkereskedelmi, its Hungarian subsidiary, said on Tuesday.
“Pfizer has been delivering to Hungary its Comirnaty vaccine developed in partnership with BioNTech according to schedule over the period of more than two months to help the country’s protection efforts,” it told MTI in a statement, noting the shipment of over 690,000 doses in March alone.
Just on Tuesday, the 15th consignment containing 165,000 doses of the vaccine arrived in the country, it said.
Pfizer delivered its first consignment to Hungary on December 26, 2020
and will substantially increase the size of its consignments from the second quarter of the year, the company said.
BioNTech and Pfizer will boost manufacturing capacity of their COVID-19 vaccine to 2.5 billion doses by the end of 2021, BioNTech said on Tuesday, as it projected sales of nearly 10 billion euros ($11.7 billion) from the product this year.
Pfizer previously said the partners would likely produce between 2.3 billion and 2.4 billion doses in 2021.
BioNTech cited its new facility in the German city of Marburg and an expansion of the pair’s network of third-party manufacturers and suppliers as drivers of the larger volumes.
“Additional measures and discussions with potential partners to further expand the manufacturing capacity and network are ongoing,” it said.
As of last week more than 200 million doses of the product, known as BNT162b2 or Comirnaty, had been supplied to more than 65 countries, while signed orders for delivery in 2021 currently amount to 1.4 billion doses, said BioNTech.
But the boost in output reflected increased demand and “discussions for additional dose commitments are ongoing”, it added.
Efforts to ramp up production at its Marburg facility, where it launched production in February after purchasing the site from Novartis last year, were making “remarkable progress”, said chief executive and co-founder Ugur Sahin.
The EU’s drugs regulator last week granted BioNTech approval for the use of COVID-19 vaccines produced at the facility, which has projected annual output of 1 billion doses.